Precision Medicine in Oncology®

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Mohammad Razaq, MD, discusses how the detection of driver mutations has changed the way treatment is approached in advanced non–small cell lung cancer.